Dynamic diversity of SARS-CoV-2 genetic mutations in a lung transplantation patient with persistent COVID-19.
Hidetoshi IgariSeiichiro SakaoTakayuki IshigeKengo SaitoShota MurataMisuzu YahabaToshibumi TaniguchiAkiko SuganamiKazuyuki MatsushitaYutaka TamuraTakuji SuzukiEiji IdoPublished in: Nature communications (2024)
Numerous SARS-CoV-2 variant strains with altered characteristics have emerged since the onset of the COVID-19 pandemic. Remdesivir (RDV), a ribonucleotide analogue inhibitor of viral RNA polymerase, has become a valuable therapeutic agent. However, immunosuppressed hosts may respond inadequately to RDV and develop chronic persistent infections. A patient with respiratory failure caused by interstitial pneumonia, who had undergone transplantation of the left lung, developed COVID-19 caused by Omicron BA.5 strain with persistent chronic viral shedding, showing viral fusogenicity. Genome-wide sequencing analyses revealed the occurrence of several viral mutations after RDV treatment, followed by dynamic changes in the viral populations. The C799F mutation in nsp12 was found to play a pivotal role in conferring RDV resistance, preventing RDV-triphosphate from entering the active site of RNA-dependent RNA polymerase. The occurrence of diverse mutations is a characteristic of SARS-CoV-2, which mutates frequently. Herein, we describe the clinical case of an immunosuppressed host in whom inadequate treatment resulted in highly diverse SARS-CoV-2 mutations that threatened the patient's health due to the development of drug-resistant variants.
Keyphrases
- sars cov
- drug resistant
- respiratory syndrome coronavirus
- genome wide
- respiratory failure
- case report
- risk assessment
- extracorporeal membrane oxygenation
- public health
- healthcare
- copy number
- escherichia coli
- dna methylation
- single cell
- coronavirus disease
- acinetobacter baumannii
- combination therapy
- stem cells
- bone marrow
- cystic fibrosis
- health information
- genetic diversity